Subject:
- Active Substance: Ertugliflozin
- Name: Steglatro®
- Therapeutic area: Type 2 diabetes mellitus
- Pharmaceutical company: MSD Sharp & Dohme GmbH
Time table:
- Start: 01.12.2021
- Final decision by G-BA: 19.05.2022
Final decision:
- a1) Insulin-naive patients without manifested cardiovascular disease who have not achieved adequate glycemic control with their current drug therapy consisting of 1 blood glucose-lowering drug:
No additional benefit proved
a2) Insulin-naive patients with manifested cardiovascular disease who have not achieved adequate glycemic control with their current drug therapy consisting of 1 blood glucose-lowering drug:
No additional benefit proved
b1) Insulin-naive patients without manifested cardiovascular disease who have not achieved adequate glycemic control with their current drug therapy consisting of 2 blood glucose-lowering drugs, for whom there is no indication for insulin therapy:
No additional benefit proved
b2) Insulin-naive patients with manifested cardiovascular disease who have not achieved adequate glycemic control with their current drug therapy consisting of 2 blood glucose-lowering drugs, for whom there is no indication for insulin therapy:
No additional benefit proved
c1) Insulin-naive patients without manifested cardiovascular disease who have not achieved adequate glycemic control with their current drug therapy consisting of ≥ 2 blood glucose-lowering drugs, who are indicated for an insulin therapy:
No additional benefit proved
c2) Insulin-naive patients with manifested cardiovascular disease who have not achieved adequate glycemic control with their current drug therapy consisting of ≥ 2 blood glucose-lowering drugs, who are indicated for an insulin therapy: No additional benefit proved
d1) Insulin-experienced patients without manifested cardiovascular disease who have not achieved adequate glycemic control with their existing insulin regimen:
No additional benefit proved
d2) Insulin-experienced patients with manifested cardiovascular disease who have not achieved adequate glycemic control with their existing insulin regimen:
No additional benefit proved